Tracers / [177Lu]Lu-pentixather
[177Lu]Lu-pentixather
Also written as [177Lu]PentixaTher; [Lu-177]PentixaTher; Lu-177 Pentixather; Lu-177-Pentixather; PentixaTher
- Radionuclide
- Lu-177 t½ 9585 min
- Modality
- Therapy
- Production route
- —
- Stage
- Investigational (first-in-human / early clinical)
- Syntheses indexed
- 15
What it is
- Compound class
- Radiolabelled cyclic pentapeptide, CXCR4 ligand (therapeutic beta-emitter conjugate)
- Target / mechanism
- Chemokine receptor CXCR4 PMID 26564323
- Clinical application
- CXCR4-directed endoradiotherapy in advanced-stage multiple myeloma with extensive intra- and extramedullary disease (first-in-human) PMID 26564323
- Theranostic pair
- <a href="/tracers/ga68-pentixafor/">ga68-pentixafor</a>
Regulatory status
- FDA
- No FDA (Drugs@FDA/openFDA): no pentixather product found
- EMA (centralised)
- No EMA medicines register export (2026-09-09): no 'pentixather' entry
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | — | 28529638 2017 Theranostics |
| Scintomics GRP / GRP-3V Scintomics | — | none | — | >98% | pentixather | 28744319 2017 Theranostics [177Lu]pentixather was prepared using a Scintomics GRP synthesis module (Scintomics, Fürstenfeldbruck, Germany). |
| — | — | — | — | — | — | 41706122 2026 Eur J Nucl Med Mol Imaging |
| Scintomics GRP / GRP-3V Scintomics | vendor cassette | — | — | — | Pentixather | 29290814 2018 Theranostics using a GRP® module (SCINTOMICS GmbH, Fürstenfeldbruck, Germany) |
| — | — | — | — | — | — | 32724470 2020 Theranostics |
| — | — | — | — | — | — | 42244984 2026 Theranostics |
| — | — | — | — | — | — | 40323995 2025 Clin Nucl Med |
| — | — | — | — | — | — | 39744224 2025 Theranostics |
| Manual synthesis | — | SPE | — | — | pentixather acetate ABX | 37989124 2024 Radiat Res Pentixather as a 1 μg/μl concentration in 300 μl of ascorbic acid buffer (50 mg/ml from Polatom, Poland) (pH 4) was mixed with 177LuCl3 (at approximately ratio of 1 μg per 37 MBq of 177Lutetium) at 95°C for 27 min with shaking (450 rpm). |
| — | — | — | — | — | — | 32724470 2020 Theranostics |
| — | — | — | — | — | — | 30850502 2019 J Nucl Med |
| Scintomics GRP / GRP-3V Scintomics | vendor cassette | — | — | — | Pentixather | 29290814 2018 Theranostics using a GRP® module (SCINTOMICS GmbH, Fürstenfeldbruck, Germany) equipped with disposable single-use cassette kits |
| Scintomics GRP / GRP-3V Scintomics | — | none | — | >98% | pentixather | 28744319 2017 Theranostics [177Lu]pentixather was prepared using a Scintomics GRP synthesis module (Scintomics, Fürstenfeldbruck, Germany) |
| — | — | — | — | — | — | 26877786 2016 Theranostics |
| — | — | — | — | — | — | 26564323 2016 J Nucl Med |
Need this precursor?We can point you to suppliers for [177Lu]Lu-pentixather, or handle the enquiry for you.
Get in touchQuality control Preliminary — inferred from compound class
- Ph. Eur. monograph
- —
- USP monograph
- —
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); Lu-177 preparation -> Lu-177m content (rule); therapeutic radiopharmaceutical -> osmolality (rule); receptor ligand with a saturable target -> molar activity (rule)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [177Lu]Lu-pentixather.
Get in touchNotes
Added from reverse module search (stage 6); 3 article(s) with Lu-177.